Ser268
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser268  -  IRS1 (human)

Site Information
SDEFRPRsKsQSssN   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 5595812
Available spectra:  1 CST
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:
lung cancer ( 1 ) , non-small cell lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:
A549 (pulmonary) ( 1 ) , HeLa (cervical) ( 2 ) , lung ( 1 ) , M059K (glial) ( 3 ) , NCI-H1355 (pulmonary) ( 1 ) , NCI-H1792 (pulmonary) ( 1 ) , NCI-H23 (pulmonary) ( 1 ) , NCI-H441 (pulmonary) ( 1 )

References 

1

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

2

Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8
19276368   Curated Info

3

Stokes M (2006) CST Curation Set: 1634; Year: 2006; Biosample/Treatment: cell line, M059K/untreated; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]
Curated Info